Skip to content

Stavudine

FDA-approved product (capsule, oral), marketed as Stavudine, Zerit, Zerit Xr.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
0 of 4

Chemical structure

Chemical structure of Stavudine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • HIV infection
  • HIV-1 infection
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Nucleoside and nucleotide reverse transcriptase inhibitors
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AF04

Repurposing investigation

No supported pathogen reaches ≥40% AI-predicted activity for Stavudine, so it is not among the repurposing candidates. Its predictions are shown below.

AI-predicted activity

AI prediction · nothing measured
  • MRSA13.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli14.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae13.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis22.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Stavudine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Virologic and Immunologic Activity of Continued Lamivudine (3TC) vs Delavirdine (DLV) in Combination With Indinavir (IDV) and Zidovudine (ZDV) or Stavudine (d4T) in 3TC-Experienced Subjects

    NCT00000882

    Registered record
    Registry ID
    NCT00000882
    Conditions
    HIV Infections
    Interventions
    Indinavir sulfate; Delavirdine mesylate; Lamivudine; Stavudine; Zidovudine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionIndinavir sulfate; Delavirdine mesylate; Lamivudine; Stavudine +1 more
    PhasePhase 2
    Registry statusCompleted
  • Safety and Effectiveness of Giving Indinavir Plus Stavudine Plus Lamivudine to HIV-Infected Children

    NCT00000901

    Registered record
    Registry ID
    NCT00000901
    Conditions
    HIV Infections
    Interventions
    Indinavir sulfate; Lamivudine; Stavudine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    Not recorded
    Completion
    2000-10
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionIndinavir sulfate; Lamivudine; Stavudine
    PhasePhase 1
    Registry statusCompleted
  • A Study to Compare The Ability of Different Anti-HIV Drugs to Decrease Viral Load After Nelfinavir (an Anti-HIV Drug)Treatment Failure

    NCT00000918

    Registered record
    Registry ID
    NCT00000918
    Conditions
    HIV Infections
    Interventions
    Indinavir sulfate; Lamivudine/Zidovudine; Ritonavir; Amprenavir; Efavirenz; Saquinavir; Lamivudine; Stavudine; Zidovudine; Didanosine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    Not recorded
    Completion
    2002-02
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionIndinavir sulfate; Lamivudine/Zidovudine; Ritonavir; Amprenavir +6 more
    PhasePhase 2
    Registry statusCompleted
  • A Study to Compare Two Different Anti-HIV Drug Regimens

    NCT00000924

    Registered record
    Registry ID
    NCT00000924
    Conditions
    HIV Infections
    Interventions
    Ritonavir; Nelfinavir mesylate; Nevirapine; Stavudine; Didanosine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    Not recorded
    Completion
    2001-06
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionRitonavir; Nelfinavir mesylate; Nevirapine; Stavudine +1 more
    PhasePhase 2
    Registry statusCompleted
  • A Study to Compare the Effectiveness of Different Anti-HIV Drug Regimens in Keeping Levels of HIV in the Blood as Low as Possible

    NCT00000939

    Registered record
    Registry ID
    NCT00000939
    Conditions
    HIV Infections
    Interventions
    Hydroxyurea; Efavirenz; Stavudine; Didanosine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    Not recorded
    Completion
    2000-01
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionHydroxyurea; Efavirenz; Stavudine; Didanosine
    PhasePhase 2
    Registry statusCompleted
  • The Effectiveness of Three Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Never Used Anti-HIV Drugs

    NCT00001067

    Registered record
    Registry ID
    NCT00001067
    Conditions
    HIV Infections
    Interventions
    Lamivudine; Stavudine; Zidovudine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    Not recorded
    Completion
    1997-11
    Enrolment
    105

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionLamivudine; Stavudine; Zidovudine
    PhasePhase 2
    Registry statusCompleted
  • A Study of an Adherence Plan to Help HIV-Positive Patients Take Their First Anti-HIV Medications Correctly

    NCT00001122

    Registered record
    Registry ID
    NCT00001122
    Conditions
    HIV Infections
    Interventions
    Nelfinavir mesylate; Efavirenz; Stavudine; Didanosine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    74

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionNelfinavir mesylate; Efavirenz; Stavudine; Didanosine
    PhasePhase 2
    Registry statusCompleted
  • Double-Blind Study of Timunox (Thymopentin) in Asymptomatic HIV-Infected Patients Receiving Either Mono (AZT or ddI) or Combination (AZT / ddI or AZT / ddC) Anti-Retroviral Therapy

    NCT00002109

    Registered record
    Registry ID
    NCT00002109
    Conditions
    HIV Infections
    Interventions
    Thymopentin; Stavudine; Zidovudine; Zalcitabine; Didanosine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionThymopentin; Stavudine; Zidovudine; Zalcitabine +1 more
    PhasePhase 3
    Registry statusCompleted
  • A Comparison of Two Anti-HIV Triple-Drug Combinations in HIV-Infected Patients

    NCT00002168

    Registered record
    Registry ID
    NCT00002168
    Conditions
    HIV Infections
    Interventions
    Indinavir sulfate; Lamivudine; Stavudine; Zidovudine; Didanosine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionIndinavir sulfate; Lamivudine; Stavudine; Zidovudine +1 more
    PhaseNot applicable
    Registry statusCompleted
  • A Phase II, Stratified, Randomized, Double-Blind, Multi-Center Study of the Safety and Efficacy of Adefovir Dipivoxil (ADF) at Two Dose Levels in Triple Combination Therapies With Protease Inhibitors (PI) and Nucleoside Reverse Transcriptase Inhibitors (RTI) for the Treatment of HIV-Infected Patient

    NCT00002184

    Registered record
    Registry ID
    NCT00002184
    Conditions
    HIV Infections
    Interventions
    Nelfinavir mesylate; Levocarnitine; Adefovir dipivoxil; Saquinavir; Lamivudine; Stavudine; Zidovudine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionNelfinavir mesylate; Levocarnitine; Adefovir dipivoxil; Saquinavir +3 more
    PhasePhase 2
    Registry statusCompleted
  • Safety and Effectiveness of Giving Combinations of Three or Four Anti-HIV Drugs to HIV-Infected Patients

    NCT00002211

    Registered record
    Registry ID
    NCT00002211
    Conditions
    HIV Infections
    Interventions
    Nelfinavir mesylate; Delavirdine mesylate; Stavudine; Didanosine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    160

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionNelfinavir mesylate; Delavirdine mesylate; Stavudine; Didanosine
    PhaseNot applicable
    Registry statusCompleted
  • A Study of Saquinavir Soft Gelatin Capsules Combined With Other Anti-HIV Drugs in HIV-1 Infected Patients

    NCT00002374

    Registered record
    Registry ID
    NCT00002374
    Conditions
    HIV Infections
    Interventions
    Ritonavir; Nelfinavir mesylate; Saquinavir; Stavudine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionRitonavir; Nelfinavir mesylate; Saquinavir; Stavudine
    PhasePhase 3
    Registry statusCompleted
  • The Safety and Effectiveness of Nevirapine Plus Nelfinavir in HIV-1 Infected Patients Who Have Taken Stavudine

    NCT00002381

    Registered record
    Registry ID
    NCT00002381
    Conditions
    HIV Infections
    Interventions
    Nelfinavir mesylate; Nevirapine; Stavudine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionNelfinavir mesylate; Nevirapine; Stavudine
    PhasePhase 1
    Registry statusCompleted
  • Effect of Indinavir Plus Two Other Anti-HIV Drugs on Blood Clotting in HIV-Positive Males With Hemophilia

    NCT00002386

    Registered record
    Registry ID
    NCT00002386
    Conditions
    HIV Infections; Hemophilia A
    Interventions
    Indinavir sulfate; Lamivudine; Stavudine; Zidovudine; Zalcitabine; Didanosine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    55

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections; Hemophilia A
    InterventionIndinavir sulfate; Lamivudine; Stavudine; Zidovudine +2 more
    PhasePhase 4
    Registry statusCompleted
  • The Safety and Effectiveness of Didanosine Plus Stavudine Plus Nevirapine Combined With MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors

    NCT00002418

    Registered record
    Registry ID
    NCT00002418
    Conditions
    HIV Infections
    Interventions
    Emivirine; Hydroxyurea; Nevirapine; Stavudine; Didanosine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionEmivirine; Hydroxyurea; Nevirapine; Stavudine +1 more
    PhasePhase 2
    Registry statusTerminated